about
Functional role of the conserved active site proline of triosephosphate isomeraseStructure-based protein engineering efforts with a monomeric TIM variant: the importance of a single point mutation for generating an active site with suitable binding propertiesCrystal structures of T. vivax nucleoside hydrolase in complex with new potent and specific inhibitorsP2-substituted N-acylprolylpyrrolidine inhibitors of prolyl oligopeptidase: biochemical evaluation, binding mode determination, and assessment in a cellular model of synucleinopathyStructures of purine nucleosidase from Trypanosoma brucei bound to isozyme-specific trypanocidals and a novel metalorganic inhibitorAn essential signal peptide peptidase identified in an RNAi screen of serine peptidases of Trypanosoma bruceiThe power metric: a new statistically robust enrichment-type metric for virtual screening applications with early recovery capabilityVisceral hypersensitivity in inflammatory bowel diseases and irritable bowel syndrome: The role of proteasesDiphenyl phosphonate inhibitors for the urokinase-type plasminogen activator: optimization of the P4 position.In vivo profiling of DPP4 inhibitors reveals alterations in collagen metabolism and accumulation of an amyloid peptide in rat plasma.Evaluation of nucleoside hydrolase inhibitors for treatment of African trypanosomiasisDiaryltriazine non-nucleoside reverse transcriptase inhibitors are potent candidates for pre-exposure prophylaxis in the prevention of sexual HIV transmission.Repositioning the substrate activity screening (SAS) approach as a fragment-based method for identification of weak binders.From human immunodeficiency virus non-nucleoside reverse transcriptase inhibitors to potent and selective antitrypanosomal compounds.Inhibitor screening and enzymatic activity determination for autophagy target Atg4B using a gel electrophoresis-based assay.ATG4B inhibitors with a benzotropolone core structure block autophagy and augment efficiency of chemotherapy in mice.In Vivo Amyloid-β Imaging in the APPPS1-21 Transgenic Mouse Model with a (89)Zr-Labeled Monoclonal Antibody.Enzyme activity and immunohistochemical localization of dipeptidyl peptidase 8 and 9 in male reproductive tissues.The role of the S1 binding site of carboxypeptidase M in substrate specificity and turn-over.Substrate Activity Screening (SAS) and Related Approaches in Medicinal Chemistry.Novel Ferroptosis Inhibitors with Improved Potency and ADME Properties.Resistance and cross-resistance profile of the diaryltriazine NNRTI and candidate microbicide UAMC01398.Vaginal expression of efflux transporters and the potential impact on the disposition of microbicides in vitro and in rabbits.The use of supersaturation for the vaginal application of microbicides: a case study with dapivirine.Schistosomicidal and molluscicidal activities of aminoalkylamino substituted neo- and norneocryptolepine derivatives.Synthesis and in vivo preclinical evaluation of an (18)F labeled uPA inhibitor as a potential PET imaging agent.Development and characterization of a solid dispersion film for the vaginal application of the anti-HIV microbicide UAMC01398.Development and in vitro evaluation of a vaginal microbicide gel formulation for UAMC01398, a novel diaryltriazine NNRTI against HIV-1.Regulation of intestinal permeability: The role of proteasesSynthesis, evaluation and structure-activity relationships of triazine dimers as novel antiviral agents.Preclinical evaluation of [111 In]MICA-401, an activity-based probe for SPECT imaging of in vivo uPA activity.Expression and spatial heterogeneity of dipeptidyl peptidases in endothelial cells of conduct vessels and capillaries.Acylated Gly-(2-cyano)pyrrolidines as inhibitors of fibroblast activation protein (FAP) and the issue of FAP/prolyl oligopeptidase (PREP)-selectivity.α-ketoheterocycles as inhibitors of Leishmania mexicana cysteine protease CPB.Structure-activity relationship studies on isoindoline inhibitors of dipeptidyl peptidases 8 and 9 (DPP8, DPP9): is DPP8-selectivity an attainable goal?Selective Inhibitors of Fibroblast Activation Protein (FAP) with a (4-Quinolinoyl)-glycyl-2-cyanopyrrolidine Scaffold.Design and evaluation of Trypanosoma brucei metacaspase inhibitors.Sorafenib tosylate inhibits directly necrosome complex formation and protects in mouse models of inflammation and tissue injury.Dipeptidyl peptidase II and leukocyte cell death.Kinetic investigation of human dipeptidyl peptidase II (DPPII)-mediated hydrolysis of dipeptide derivatives and its identification as quiescent cell proline dipeptidase (QPP)/dipeptidyl peptidase 7 (DPP7).
P50
Q27643363-E6D6FC39-F4C8-4A37-9616-D78AD0227233Q27649751-CE2B7EFB-9978-458E-BC5C-6402E43213C7Q27654085-E5401732-C182-4CBF-817C-7F1DC9DCFE6FQ27683169-78C2F8F7-85CB-49FB-99B3-88E0CC510974Q27685304-3D572440-CDAC-45D2-9DDD-6A29317A164FQ28545105-7FA802C3-35EB-47A5-9A5F-5B23CAD28A5FQ28745255-8DF7F8AF-EA93-4748-84FB-9904C420B20BQ28818844-5EB872C4-387E-44CE-9F84-A3949A157436Q33257437-FDACE088-0650-4970-A9E2-1384C61615E1Q33378379-E760F9C9-538A-48F4-B321-756E63DEB752Q33535651-E0CD12D5-6E8A-4E97-A775-4B8441F5B54CQ34706527-880B5E10-E569-43CA-B3CE-94C555C80454Q35231270-9B74AA11-B6E2-4391-BDF2-D7045B49A22EQ35242901-BF01A49D-8B01-4B99-B35F-84B4F375B7ABQ36102666-17CD867C-7D02-4CB0-86D2-4C4141F9AD04Q36412834-67CC0DEC-DEC9-4C03-8406-B5EC4598BC98Q36748573-3F350F1F-2950-498D-9032-CAC1E551E902Q37212254-A993E543-5A2E-40F5-9654-2C911D0777A8Q38305977-018C2401-CDD9-468C-B86D-CD83EBDDC7C5Q38722942-BC4C93D2-4739-4D49-BE5D-314417AF0482Q38809633-87F78BEF-0AC4-4355-A09E-E3395A7A1B2CQ38879629-B3F10BFF-6288-41F7-B26F-00DEEB007ADEQ38946716-CB4282A1-9CAF-442D-9802-49C1E3D407DFQ38955501-C1DD1EAD-E7E5-4C01-BDA1-6A5827258885Q38984212-AAF16235-4D42-4B8B-B8C0-D2D310D91FA4Q39001146-67F2A9E2-F8A3-4412-91AD-C04A3402B6D7Q39031040-72B0C85E-CCEB-4453-BEE0-88C210239CC9Q39031043-E67AF412-EF2E-4E18-B7EC-110417E5108CQ39239228-BA531D19-92A4-4A29-B2AC-03FEAE7C52C9Q39256043-584AAAE9-2A83-4D61-8766-5F25C7ECBEFDQ39456396-DB4C442D-4437-429C-B168-A90260E03ACEQ39613724-FB949ABA-A512-47B9-8935-6EE0900E3EE8Q39626089-D2FAB292-127A-4584-8389-1D974B7A2199Q39662647-2B48586F-EF94-4FCA-A044-C44DA53F0D70Q39734783-1BC1D0F7-2B8A-44F9-99B7-9C124FD25FF8Q39769132-91FFF1D3-CC63-414A-9E02-22DFE9D8EC81Q39807680-15E44D60-A558-44E3-B3AF-2F260E4CA012Q40153668-22D869EF-5262-415A-96CC-D36EBF16B030Q40275294-ED1BB3CF-EFCF-4086-8F1D-7007BC1A203AQ41790660-B2B2C73B-71BF-475E-9443-F1DD728F6C86
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Koen Augustyns
@ast
Koen Augustyns
@en
Koen Augustyns
@es
Koen Augustyns
@sl
type
label
Koen Augustyns
@ast
Koen Augustyns
@en
Koen Augustyns
@es
Koen Augustyns
@sl
prefLabel
Koen Augustyns
@ast
Koen Augustyns
@en
Koen Augustyns
@es
Koen Augustyns
@sl
P1053
C-1102-2008
P106
P21
P31
P3829
P496
0000-0002-5203-4339